MEMORANDUM FOR ALMAJCOM/SG

FROM:   HQ USAF/SG3
        110 Luke Avenue, Room 400
        Bolling AFB DC 20032-7050

SUBJECT:   Change in Administration Route and Dosing Schedule for the Anthrax Vaccine Adsorbed
           (AVA)

The U.S. Food and Drug Administration has approved changes to the AVA administration route
and dosage schedule. The Military Vaccine Agency (MILVAX) has issued instructions that implement
these changes across the DoD (Atech 1); the Anthrax Vaccine Policy has not changed. AF Healthcare
Providers and Immunization Technicians will begin adhering to the following approved changes
immediately:

a. Administration of AVA via the intramuscular (IM) route.

b. AVA vaccine will be given as a series of five 0.5-ml IM doses at 0, 4 weeks, 6
   months, 12 months, and 18 months with annual boosters.

c. Resume any missed or prolonged delay in the primary AVA series with administration
   of the next dose in the vaccine series; do not restart the vaccine series at the initial dose. Do not
   administer the AVA vaccine on a compressed or accelerated schedule.

At this time, the Air Force Complete Immunization Tracking Application (AFCITA) and
Preventive Health Assessment/Individual Medical Readiness Software (PIMR) have not been updated to
accept the new AVA dosage schedule. Therefore, implementing the 5-dose schedule prior to receiving
the updated software may impact immunization and individual medical readiness numbers in the interim.
AFCITA and PIMR will be updated and beta-tested at selected locations as soon as possible before the
software is released AF-wide.

My POC for this action is Lt Col Michael Lundy, AFMSA/SG3PM, (202) 404-2735, DSN 297-
2735, or Michael.Lundy@Pentagon.af.mil.

Attachment:
MILVAX Memo, 16 Dec 08
MEMORANDUM FOR SEE DISTRIBUTION

SUBJECT: Implementation Instructions for Change in Route and Change in Dosing Schedule for the Anthrax Vaccine Adsorbed (AVA) in the Department of Defense Anthrax Vaccine Immunization Program (AVIP)

1. References:


Military Vaccine Agency

SUBJECT: Implementation Instructions for Change in Route and Change in Dosing Schedule for the Anthrax Vaccine Adsorbed (AVA) in the Department of Defense Anthrax Vaccine Immunization Program (AVIP)


2. Purpose: To provide instructions to Service representatives on the change in the route of administration and the change in the dosing schedule of Anthrax Vaccine Adsorbed (AVA) as part of the Department of Defense (DoD) Anthrax Vaccine Immunization Program (AVIP).

3. Summary: The FDA has approved a change in route of administration for the anthrax vaccine adsorbed (AVA) from a subcutaneous (SC) injection to intramuscular (IM). The FDA has also approved a change in the vaccination series by removing the 2-week dose post-vaccination and asserting the safety and effectiveness of the new 5-dose regimen.

4. Timeline:

   a. Effective 11 December 2008: DoD healthcare providers will begin administering AVA via the intramuscular (IM) route per the FDA approved manufacture’s recommendation.

   b. Effective 11 December 2008: DoD healthcare providers will begin adhering to the newly FDA approved manufacturer recommended 5 dose vaccination series as described in the vaccine prescribing information.

5. Anthrax Vaccine Immunization Program (AVIP) Policy: The DoD policy for AVIP remains the same. This new route and schedule is a clinical change and does not alter the population being vaccinated or the previous requirements of AVIP.

6. Clinical Requirements: Anthrax vaccination will be given as a series of five 0.5-ml intramuscular doses at 0, 4 week, 6 month, 12 month, and 18 month, with boosters given annually to maintain immunity. Injections are given in the deltoid region of the upper arm. The significant changes are:

   a. As stated in prior policies, doses of the vaccine should not be administered on a compressed or accelerated schedule. The doses will be administered intramuscularly at 0, 4 week, 6 month, 12 month, and 18 month for the primary series and yearly boosters thereafter. For an individual who is late or has missed a dose in the standard immunization schedule, the following procedures shall be followed:

      1) Resume the primary series with administration of the next dose in the series. Administer subsequent doses of vaccine at intervals based on the date the last dose was given, not when it was originally scheduled.
Military Vaccine Agency

SUBJECT: Implementation Instructions for Change in Route and Change in Dosing Schedule for the Anthrax Vaccine Adsorbed (AVA) in the Department of Defense Anthrax Vaccine Immunization Program (AVIP)

2) Per the Advisory Committee on Immunization Practices (ACIP) recommendations, the primary AVA series does not need to be restarted regardless of time elapsed since last dose. Once the primary series of five doses is complete, the primary series is never repeated. Available AVA specific data suggests that significantly increasing the interval between doses does not adversely affect immunogenicity or safety. Therefore, as with other vaccines, interruption of the vaccination schedule does not require restarting the entire series or the addition of extra doses.

3) If an annual booster has not been administered on time, administer the booster dose at the earliest possible date, adjusting the subsequent booster schedule accordingly.

7. Vaccine Safety:

a. Researchers at the Centers for Disease Control and Prevention (CDC) conducted a randomized double-blind study and found that primary series dose reduction from 6 doses to 5 doses over an 18 month period receive the same benefit of protection from anthrax vaccine.

b. Results demonstrated that 4 subcutaneous (SC), 4 intramuscular (IM), and 3 IM regimens provide equivalent immunological priming by the 7th month. The IM administration significantly reduced the occurrence of local adverse events at the injection site.

c. Our scientific understanding of the safety profile for anthrax vaccination is shaped by over 30 human safety studies conducted by both military and independent civilian expert panels, including a comprehensive evaluation by the National Academy of Sciences and its Institute of Medicine (IOM). After a two-year review, the IOM concluded that scientific evidence for the vaccine’s safety and effectiveness is sound.

8. Education Requirements: Prior to vaccination with AVA all vaccinees must receive a copy of the Vaccine Information Statement (VIS) and the DoD Anthrax Individual Information Trifold Brochure. These are shipped to clinics at no cost in the same quantity as the ordered vaccine. Additionally, clinics may request additional copies through MILVAX by phone at 877-GET-VACC or email at Vaccines@amedd.army.mil. These products are also available on-line for downloading at:

9. Vaccine Ordering, Storage, and Handling Procedures:
Military Vaccine Agency
SUBJECT: Implementation Instructions for Change in Route and Change in Dosing Schedule for the Anthrax Vaccine Adsorbed (AVA) in the Department of Defense Anthrax Vaccine Immunization Program (AVIP)

a. The ordering process will remain the same. Customers will order from the USAMMA-DOC.

b. The AVA vaccine will be distributed and stored at 2-8°C (36-46°F).

c. DoD uses the same FDA approved vaccine that is maintained in the Strategic National Stockpile. This vaccine is approved for use in the DoD.

10. Immunization Record Keeping Procedures. There is no change to the immunization record keeping requirements. Every vaccination must be entered into a DoD-approved electronic immunization tracking system.

11. POC for this message is LTC Patrick Garman, COM: 703-681-5101 or DSN: 761-5101.

MICHAEL J. KRUKAR
COL, MS
Director, Military Vaccine Agency

DISTRIBUTION:
CBRN Defense Policy, FHP&R, OASD(HA) (ATTN: CAPT Hottenstein)
Army Immunization Policy POC (ATTN: COL Stanek)
Navy Immunization Policy POC (ATTN: CAPT Naito)
Air Force Immunization Policy POC (ATTN: Lt Col Lundy)
Marine Corps Immunization Policy POC (ATTN: CDR Feeks)
Coast Guard Immunization Policy POC (ATTN: CAPT Arnold)
Joint Staff Immunization Policy POC (ATTN: MAJ Fea)
USAMMA Distribution Operations Center (ATTN: LTC Williams)